Skip to content

Study · Observational study · 2025

6 results

Effects of semaglutide on one-year medical costs among patients with obesity or overweight in US real world setting.

Arora P, Michalak W, Zhao Z, Fiasconaro M, Hong Y, Zhao X, Ó Hartaigh B, Alvarez S, Fitch A

Expert review of pharmacoeconomics & outcomes research9 Oct 2025

PMID41059919 (opens in a new tab)DOI10.1080/14737167.2025.2570688 (opens in a new tab)PepBankPUB-41059919
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In US adults with obesity or overweight, semaglutide 2.4 mg users had 37% lower incidence of all-cause inpatient visits than obesity medication non-users over 12 months.

    In plain wordsIn US adults with obesity or overweight, people on semaglutide 2.4 mg had fewer hospital stays than matched people not on obesity drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause inpatient visits
    Study

    n: not reported in source

    Comparator
    Obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    2.4 mg once weeklyAs given in this study (human).

    Measurements

    Lower all-cause inpatient visit incidence
    37%
    semaglutide vs non-users

    Source sentences

    Summary
    Patients treated with semaglutide 2.4 mg vs OM non-users had 37% and 21% lower incidence of all-cause inpatient (IP) and emergency room (ER) visits, respectively, and 45% and 29% lower incidence of ORC-related IP and ER visits, respectively.
    2 context sentences
    Summary · context
    This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database.
    Summary · context
    Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users.
  2. 02HumanObservational studyEfficacy outcome

    In US adults with obesity or overweight, semaglutide 2.4 mg users had 21% lower incidence of all-cause emergency room visits than obesity medication non-users over 12 months.

    In plain wordsIn US adults with obesity or overweight, people on semaglutide 2.4 mg had fewer emergency room visits than matched people not on obesity drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause emergency room visits
    Study

    n: not reported in source

    Comparator
    Obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    2.4 mg once weeklyAs given in this study (human).

    Measurements

    Lower all-cause ER visit incidence
    21%
    semaglutide vs non-users

    Source sentences

    Summary
    Patients treated with semaglutide 2.4 mg vs OM non-users had 37% and 21% lower incidence of all-cause inpatient (IP) and emergency room (ER) visits, respectively, and 45% and 29% lower incidence of ORC-related IP and ER visits, respectively.
    2 context sentences
    Summary · context
    This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database.
    Summary · context
    Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users.
  3. 03HumanObservational studyEfficacy outcome

    In US adults with obesity or overweight, semaglutide 2.4 mg users had 45% lower incidence of inpatient visits related to obesity-related complications than non-users.

    In plain wordsPeople on semaglutide 2.4 mg had fewer hospital stays for obesity-related problems than matched people not on obesity drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseObesity-related complication inpatient visits
    Study

    n: not reported in source

    Comparator
    Obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    2.4 mg once weeklyAs given in this study (human).

    Measurements

    Lower ORC-related inpatient visit incidence
    45%
    semaglutide vs non-users

    Source sentences

    Summary
    Patients treated with semaglutide 2.4 mg vs OM non-users had 37% and 21% lower incidence of all-cause inpatient (IP) and emergency room (ER) visits, respectively, and 45% and 29% lower incidence of ORC-related IP and ER visits, respectively.
    2 context sentences
    Summary · context
    This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database.
    Summary · context
    Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users.
  4. 04HumanObservational studyEfficacy outcome

    In US adults with obesity or overweight, semaglutide 2.4 mg users had 29% lower incidence of emergency room visits related to obesity-related complications than non-users.

    In plain wordsPeople on semaglutide 2.4 mg had fewer emergency room visits for obesity-related problems than matched people not on obesity drugs.

    Peptide
    Semaglutide
    Outcome
    DecreaseObesity-related complication emergency room visits
    Study

    n: not reported in source

    Comparator
    Obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    2.4 mg once weeklyAs given in this study (human).

    Measurements

    Lower ORC-related ER visit incidence
    29%
    semaglutide vs non-users

    Source sentences

    Summary
    Patients treated with semaglutide 2.4 mg vs OM non-users had 37% and 21% lower incidence of all-cause inpatient (IP) and emergency room (ER) visits, respectively, and 45% and 29% lower incidence of ORC-related IP and ER visits, respectively.
    2 context sentences
    Summary · context
    This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database.
    Summary · context
    Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users.
  5. 05HumanObservational studyEfficacy outcome

    In US adults with obesity or overweight, all-cause total medical costs were 11% lower with semaglutide 2.4 mg than in non-users, a saving of $3,342 at 12 months.

    In plain wordsPeople on semaglutide 2.4 mg had 11% lower medical costs than matched people not on obesity drugs, a saving of $3,342 in a year.

    Peptide
    Semaglutide
    Outcome
    DecreaseAll-cause total medical costs
    Study

    n: not reported in source

    Comparator
    Obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    2.4 mg once weeklyAs given in this study (human).

    Measurements

    Lower all-cause medical costs
    11%
    semaglutide vs non-users

    Source sentences

    Summary
    All-cause and ORC-related total medical costs were lower among patients treated with semaglutide 2.4 mg (11% and 15% lower, respectively), translating to an observed savings of $3,342 and $2,408 at 12 months.
    2 context sentences
    Summary · context
    This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database.
    Summary · context
    Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users.
  6. 06HumanObservational studyEfficacy outcome

    In US adults with obesity or overweight, medical costs related to obesity-related complications were 15% lower with semaglutide 2.4 mg than in non-users, a saving of $2,408 at 12 months.

    In plain wordsPeople on semaglutide 2.4 mg had 15% lower costs for obesity-related problems than matched people not on obesity drugs, saving $2,408 in a year.

    Peptide
    Semaglutide
    Outcome
    DecreaseObesity-related complication medical costs
    Study

    n: not reported in source

    Comparator
    Obesity medication non-users
    Outcome group
    Healthcare costs and utilization · Whole body
    Studied dose
    2.4 mg once weeklyAs given in this study (human).

    Measurements

    Lower ORC-related medical costs
    15%
    semaglutide vs non-users

    Source sentences

    Summary
    All-cause and ORC-related total medical costs were lower among patients treated with semaglutide 2.4 mg (11% and 15% lower, respectively), translating to an observed savings of $3,342 and $2,408 at 12 months.
    2 context sentences
    Summary · context
    This retrospective real-world study evaluated HCRU and costs (excluding pharmacy) among patients with obesity or overweight and ≥1 ORC in the Komodo Healthcare Map database.
    Summary · context
    Baseline characteristics of patients starting OW semaglutide 2.4 mg treatment were matched to obesity medication (OM) non-users.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    11 Oct 2026, 00:04 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:06 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.